Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients: a Genomic Epidemiology Study
Monitoring of antimicrobial resistance (AMR) based on metagenomics analyses in pneumonia patients is critical for optimizing clinical diagnosis and treatment and improving clinical prognosis. This study is designed to ask the following key questions: 1. What is the microbiome maps of patients with severe pneumonia and mild pneumonia ? 2. How many pathogen resistance genes are carrying in severe pneumonia and mild pneumonia ? 3. What is the genetic diversity of key pathogens detected in severe pneumonia and mild pneumonia during 2019-2025?
• Patients clinically diagnosed as severe pneumonia and mild pneumonia are diagnosed according to the Guidelines for the diagnosis and Treatment of community-acquired pneumonia in Adults (2019 edition) formulated by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA), who meet 1 of the following major criteria or ≥3 minor criteria can be diagnosed. The diagnostic criteria for severe and mild pneumonia in children were adopted by the British Thoracic Society (BTS) in 2011.
• Clinical examination was performed, and there was biospecimen (nasopharyngeal swab, oropharyngeal swab, bronchoalveolar lavage fluid, sputum, blood, hydrothorax, lung tissue) remaining in the clinical microbiological examination.